文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

ST 段抬高型心肌梗死患者脂蛋白(a)水平的变化——STEMI-Lipids 研究。

Changes in Lipoprotein(a) Levels in People after ST Elevation Myocardial Infarction-The STEMI-Lipids Study.

机构信息

Division of Cardiology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.

Trials Unit for Interdisciplinary Metabolic Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.

出版信息

Int J Mol Sci. 2023 Oct 24;24(21):15531. doi: 10.3390/ijms242115531.


DOI:10.3390/ijms242115531
PMID:37958516
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10647358/
Abstract

Lipoprotein(a) (Lp(a)) is considered an independent risk factor for cardiovascular diseases. The plasma concentration of Lp(a) is largely genetically determined but varies over a wide range within the population. This study investigated changes in Lp(a) levels after an acute myocardial infarction. Patients who underwent coronary angiography due to an ST elevation myocardial infarction were enrolled ( = 86), and Lp(a) levels were measured immediately after the intervention, one day, two days, and at a post-discharge follow-up visit at 3 to 6 months after the acute myocardial infarction. Median Lp(a) levels increased from a median of 7.9 mg/dL (3.8-37.1) at hospital admission to 8.4 mg/dL (3.9-35.4) on the following day, then to 9.3 mg/dL (3.7-39.1) on day two ( < 0.001), and to 11.2 mg/dL (4.4-59.6) at the post-discharge follow-up ( < 0.001). Lp(a) levels were the lowest during the acute myocardial infarction and started to increase significantly immediately thereafter, with the highest levels at the post-discharge follow-up. The moderate but significant increase in Lp(a) in people with acute myocardial infarction appears to be clinically relevant on an individual basis, especially when specific Lp(a) cut-off levels are supposed to determine the initiation of future treatment. Hence, a repeated measurement of Lp(a) after myocardial infarction should be performed.

摘要

脂蛋白(a)(Lp(a))被认为是心血管疾病的独立危险因素。血浆 Lp(a)浓度在很大程度上是由遗传决定的,但在人群中差异很大。本研究探讨了急性心肌梗死后 Lp(a)水平的变化。因 ST 段抬高型心肌梗死而行冠状动脉造影的患者被纳入研究(n=86),并在介入治疗后即刻、第 1 天、第 2 天以及急性心肌梗死后 3 至 6 个月的出院后随访时测量 Lp(a)水平。Lp(a)水平中位数从入院时的 7.9mg/dL(3.8-37.1)升高至第 2 天的 8.4mg/dL(3.9-35.4)(<0.001),然后升至第 3 天的 9.3mg/dL(3.7-39.1)(<0.001),再升至出院后随访时的 11.2mg/dL(4.4-59.6)(<0.001)。Lp(a)水平在急性心肌梗死后最低,并在随后立即显著升高,出院后随访时达到最高水平。急性心肌梗死后 Lp(a)的中度但显著增加似乎在个体基础上具有临床相关性,特别是当特定的 Lp(a)切点水平被用于决定未来治疗的开始时。因此,建议在心肌梗死后重复测量 Lp(a)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b0d/10647358/7090de2cc9e6/ijms-24-15531-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b0d/10647358/7090de2cc9e6/ijms-24-15531-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b0d/10647358/7090de2cc9e6/ijms-24-15531-g001.jpg

相似文献

[1]
Changes in Lipoprotein(a) Levels in People after ST Elevation Myocardial Infarction-The STEMI-Lipids Study.

Int J Mol Sci. 2023-10-24

[2]
Lipoprotein(a) Is Associated with Thrombus Burden in Culprit Arteries of Younger Patients with ST-Segment Elevation Myocardial Infarction.

Cardiology. 2023

[3]
Prognostic impacts of diabetes status and lipoprotein(a) levels in patients with ST-segment elevation myocardial infarction: a prospective cohort study.

Cardiovasc Diabetol. 2023-6-26

[4]
Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction.

Heart Vessels. 2016-12

[5]
Plasma Lipoprotein-Associated Phospholipase A2 Level Is an Independent Predictor of High Thrombus Burden in Patients With Acute ST-segment Elevation Myocardial Infarction.

Int Heart J. 2016-12-2

[6]
Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction.

Br Heart J. 1994-4

[7]
Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up.

Eur Heart J Open. 2023-4-5

[8]
Lipoprotein(a) plasma levels are not associated with survival after acute coronary syndromes: An observational cohort study.

PLoS One. 2020-1-9

[9]
Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.

Clin Lab. 2012

[10]
Impact of Postprocedural High-Sensitivity C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk with ST-Segment Elevation Myocardial Infarction With Percutaneous Coronary Intervention.

Am J Cardiol. 2021-7-1

引用本文的文献

[1]
Diagnostic value of the diagonal earlobe crease in combination with lipoprotein(a) in coronary heart disease.

Sci Rep. 2025-7-1

[2]
2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.

Arch Med Sci. 2025-2-22

[3]
Prevalence of Lp(a) in a real-world Portuguese cohort: implications for cardiovascular risk assessment.

Lipids Health Dis. 2025-1-18

[4]
The nonlinear association between lipoprotein(a) and major adverse cardiovascular events in acute coronary syndrome patients with three-vessel disease.

Sci Rep. 2025-1-11

[5]
New data allow to better understand the secrets of lipoprotein(a): is that for sure?

Eur Heart J Open. 2024-8-31

本文引用的文献

[1]
Inclisiran: A New Pharmacological Approach for Hypercholesterolemia.

Rev Cardiovasc Med. 2022-11-3

[2]
Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up.

Eur Heart J Open. 2023-4-5

[3]
Effect of Different Types and Dosages of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) Levels: A Network Meta-analysis.

J Cardiovasc Pharmacol. 2023-6-1

[4]
Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia-The Future Is Here.

Pharmaceutics. 2023-1-30

[5]
New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a).

J Lipid Atheroscler. 2023-1

[6]
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.

N Engl J Med. 2022-11-17

[7]
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.

Eur Heart J. 2022-10-14

[8]
Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.

JAMA Cardiol. 2022-7-1

[9]
Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol.

J Am Coll Cardiol. 2022-3-22

[10]
Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target.

Heart. 2022-12-13

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索